Selecta Biosciences has developed chimeric antigen receptors (CARs) targeting BCMA, enhancing CAR T cell binding and killing of cancer cells. The patent covers proteins with specific antigen-binding portions for improved efficacy in cancer treatment. GlobalData’s report on Selecta Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Selecta Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Selecta Biosciences's grant share as of May 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric antigen receptors for improved cancer cell killing
A recently granted patent (Publication Number: US11999773B2) discloses a protein with an antigen-binding portion specifically targeting B-Cell Maturation Antigen (BCMA). The antigen-binding portion of the protein includes various heavy and light chain complementarity determining regions (CDRs) with specific sequences, as outlined in the claims. These sequences, such as SEQ ID NOs: 1-18, play a crucial role in the protein's ability to bind to BCMA effectively.
Furthermore, the patent claims specify different combinations of CDR sequences within the protein, highlighting the importance of these specific sequences in the protein's functionality. Additionally, the patent mentions the potential application of the protein as a bispecific antibody, indicating its versatility and potential in therapeutic interventions targeting BCMA. This patent provides valuable insights into the development of novel protein-based therapeutics for conditions where targeting BCMA is beneficial, such as certain types of cancer.
To know more about GlobalData’s detailed insights on Selecta Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
